Exchange: NASDAQ·Updated 07:30 PM EDT
ANL logo

ANL Adlai Nortye Ltd. American

$10.28
$0.08
(0.78%)
Today
Closed $10.28
$0.00
(0.00%)
After Hours
Mkt Cap$603.79M
Vol44,559.00

About ANL

Adlai Nortye Group Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
51

Neutral Sentiment

How do you feel about ANL?

focafoca99
$ANL scheduled an oral presentation on its AN4035 program at the 38th EORTC-NCI-AACR Symposium.
Merlintrader
$ANL — AN4035 oral presentation at EORTC-NCI-AACR Symposium on 19 Nov in Barcelona. Information only — not investment advice. More details in our hub.
focafoca99
$ANL shared a clinical collaboration with Lilly and Merck KGaA to evaluate AN4035 plus cetuximab.
focafoca99
$ANL has held an extraordinary shareholders meeting where all resolutions were approved.

Advertisement|Remove ads.